zur Startseite
Dates
Thursday,

Veranstaltung

Veranstalter, Ort
News/Publications

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate Trial

Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey V Matous, David MacDonald, Constantine S Tam, Olivier Tournilhac, Shuo Ma, Steven P Treon, Albert Oriol, Jerry Ping, Eva M Briso, Israel Arango-Hisijara, Meletios A Dimopoulos
read more ›
 

Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia

Lisa Marie Kaiser, Mirja Harms, Daniel Sauter, Vijay P S Rawat, Mirco Glitscher, Eberhard Hildt, Daniel Tews, Zachary Hunter, Jan Münch, Christian Buske
read more ›
 

Clinical Intergroup

Clinical Intergroup

 

The ECWM is based on a clinical intergroup connecting all major clinical national study groups such as:

  • BNLI
  • Czech Myeloma Group
  • FIL Italian Intergroup
  • FCGCLLWM Group
  • GLA/OSHO
  • Greek Myeloma Study Group 
  • HOVON 
  • Nordic Lymphoma Group
  • Portuguese Lymphoma Study Group
  • Spanish Study Group 

The ECWM is associated with the Australasian Leukaemia & Lymphoma Goup (ALLG). This clinical intergroup forms a unique platform for setting up large clinical and innovative trials in a rare disease such as WM.

 

Currently several clinical trials are initiated which offer patients with WM novel therapeutic approaches in the setting of well controlled clinical trials.